International Journal of Scientific & Technology Research

Home About Us Scope Editorial Board Blog/Latest News Contact Us
10th percentile
Powered by  Scopus
Scopus coverage:
Nov 2018 to May 2020


IJSTR >> Volume 7 - Issue 1, January 2017 Edition

International Journal of Scientific & Technology Research  
International Journal of Scientific & Technology Research

Website: http://www.ijstr.org

ISSN 2277-8616

Burkholderia Cepacia Complex Among Intensive Care Unit Patients In Two Private Hospitals In Alexandria

[Full Text]



Hadir El Kady, Osama Nasr El-Deen Mohamed, Amani Farouk Abaza , Yasser Hassan Mousa Zidan



Burkholderia ; BCC; ICU patients; BCSA medium; RapID NF Plus system



Burkholderia cepacia complex (BCC) is a group of 17 closely-related species that emerged as an important opportunistic pathogen. It causes serious infections in clinical settings because of its high intrinsic multiple antibiotic resistance and because it survives and multiplies in aqueous hospital environments including disinfectants. Infections caused by BCC include bacteremia, urinary tract infections, septic arthritis, peritonitis and respiratory tract infections; particularly in patients with cystic fibrosis (CF). Hemodialysis, permanence in intensive care units (ICUs), use of central venous catheters, and endotracheal tubes are recognized as risk factors contributing to BCC acquisition. B. cepacia selective agar (BCSA) is rapid efficient and for selective isolation of BCC. The RapID NF Plus is an accurate, rapid, easy system to identify BCC in four hours. This cross-sectional study aimed to study the occurrence of BCC infection among ICU patients in two private hospitals in Alexandria during a 4-month period from February to May 2016. Comparison of isolation of B. cepacia on conventional media and on BCSA, besides identification of isolates by RapID NF Plus system was also aimed at. Conventional media and BCSA medium were used to isolate and identify BCC in 150 examined samples. Further confirmation of BCC isolates was done using RapID NF Plus system and their antimicrobial susceptibility pattern was detected.Causative agents were isolated from 74% of samples. The infection rate was highest in the third week of hospitalization. BCC was isolated from 7.2% of samples. The highest rate of isolation occurred in patients with pulmonary diseases. All BCC isolates were found to be multiple drug resistant (MDR) but were highly susceptible to ceftazidime, meropenem, and piperacillin- tazobactam.



[1] J.J. LiPuma, T. Coenye, P. Vandamme and R.W. John, Taxonomy and Identification of the Burkholderia cepacia Complex, J Clin Microbiol, 39(10),3427, 2001.

[2] P. Vandamme and P. Dawyndt, Classification and identification of the Burkholderia cepacia complex: Past, present and future, Syst Appl Microbiol, 34: 87-95, 2011.

[3] T.J. Kidd, J.M. Douglas, H.A. Bergh, C. Coulter and S.C. Bell, Burkholderia cepacia complex epidemiology in persons with cystic fibrosis from Australia and New Zealand. Res Microbiol, 159: 194-9, 2008.

[4] J.J. Lipoma, Update on the Burkholderia cepacia complex, Curr Opin Pub Med, 11:528-33, 2005.

[5] A. Sousa, G. Ramos and H. Leitão, Burkholderia cepacia Complex: Emerging Multihost Pathogens Equipped with a Wide Range of Virulence Factors and Determinants. Review article, Int J Microbiol, 2011:1-9, 2011.

[6] D.K. Matthaiou, E. Chasou, S. Amatzidis and P. Tsolkas, A case of bacteremia due to Burkholderia cepacian in a patient without cystic fibrosis, Respiratory Med CME. 4: 144-5, 2011.

[7] R.M. Donlan, Biofilms: Microbial life on surfaces, Emerg Infect Dis. 8:881-90,2002.

[8] R.P. Vonberg and P. Gastmeier, Hospital-acquired infections related to contaminated substances, J Hosp Infect, 65: 15–23, 2007.

[9] B. De Smet, C. Veng, L. Kruy, C. Kham, J. Van Griensven, C. Peeters, et al., Outbreak of Burkholderia cepacia bloodstream infections traced to the use of Ringer lactate solution as multiple-dose vial for catheter flushing, Phnom Penh, Cambodia, Clin Microbiol Infect, 19(9):832-7, 2013.

[10] L.M. Paul, A. Hegde, T. Pai, S. Shetty, S. Baliga and S. Shenoy, An Outbreak of Burkholderia cepacia Bacteremia in a Neonatal Intensive Care Unit, Indian J Pediatr, 83(4):285-8, 2016.

[11] D.B. Shelly, T. Spilker, E.J. Gracely, T. Coenye, P. Vandamme and J.J. LiPuma, Utility of commercial systems for identification of Burkholderia cepacia complex from cystic fibrosis sputum culture, J Clin Microbiol, 38(8):3112-5, 2000.

[12] S.M. Bhise, V.A. Rahangdale and M.S. Qazi, Burkholderia cepacia, An Emerging Cause Of Septicemia- An Outbreak In A Neonatal Intensive Care Unit From A Tertiary Care Hospital Of Central India. JDMS, 10 (3): 41-43, 2013.

[13] J.F. Mac Faddin, Biochemical tests for identification of medical bacteria, 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins, p. 411-80, 2000.

[14] S. Maloney, C. Engler and R. Norton, Evaluation of the Remel RapID NF plus rapid biochemical method for identification of Burkholderia pseudomallei, J Clin Microbiol, 52(6):2175-6, 2014.

[15] RapID systems. Thermo scientific Remel microbiology products. Available from http://www.remel.com/Clinical/DiagnosticTests/RapIDSystem.aspx. [Accessed on: 20 Sep, 2017]

[16] A.W. Bauer, W.M. Kirby, J.C. Sherris and M. Turck, Antibiotic susceptibility testing by a standardized single disk method, Am J Clin Pathol, 45(4):493-6, 1966.

[17] J.B. Patel, F.R. Cockerill, J. Alder, P.A. Bradford, G.M. Eliopoulos, D.J. Hardy et al., Performance standards for antimicrobial susceptibility testing; Twenty-fourth informational supplement. M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI), 2014.

[18] L.A. Kirkpatrick and B.C. Feeney, A simple guide to IBM SPSS statistics for version 20.0. Student ed. Belmont, Calif.: Wadsworth, Cengage Learning; 2013.

[19] J.J. LiPuma, Burkholderia cepacia epidemiology and pathogenesis: implications for infection control, Curr Opin Pulm Med, 4:337–441, 1998.

[20] J.D. Mc Menamin, T.M. Zaccone, T.Coenye, P. Vandamme and J.J. LiPuma, Misidentification of Burkholderia cepacia in U.S. cystic fibrosis treatment centers: an analysis of 1051 recent sputum isolates, Chest, 117:1661–5, 2000.

[21] V. Gautam, L. Singhal and P. Ray, Burkholderia cepacia complex: Beyond pseudomonas and Acinetobacter, Indian J Med Microbiol, 29:4-12, 2011.

[22] C. Gales, N. Jones, S. Andrade and S. Sader , Antimicrobial susceptibility patterns of unusual non fermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002), Mem Inst Oswaldo Cruz, 100(6):571-8, 2005.

[23] N. Omar, H. Abd El Raouf, H. Okasha and N. Nabil, Microbiological assessment of Burkholderia cepacia complex (BCC) isolates in Alexandria Main University Hospital, Alex J Med, 51: 41-6, 2015.

[24] M. Dizbay, O. Tunccan, B. Sezer, F. Aktas and D. Arman, Nosocomial Burkholderia cepacia infections in a Turkish university hospital: a five-year surveillance, J Infect Dev Ctries, 3(4):273-7, 2009.

[25] D. Henry, M. Campbell, C. Mc Gimpsey, A. Clarke, L. Louden, J.L. Burns, et al., Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients with cystic fibrosis, J Clin Microbiol, 37:1004–7, 1999.

[26] S. Eram, Q. Nejad, G. Khatami and N. Nafissi, Detection of Burkholderia cepacia complex in patients with cystic fibrosis, Tanaffos, 3(9): 47-52, 2004.

[27] D.L. Kiska, A. Kerr, M.C. Jones, J.A. Caracciolo, B. Eskridge, M. Jordan, et al., Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis, J Clin Microbiol, 34(4):886-91, 1996.

[28] Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement. M100-S20 Wayne, PA: CLSI; 2010.

[29] M. Katsiari, Z. Roussou, K. Tryfinopoulou, A. Vatopoulos, E. Platsouka and A.Maguina, Burkholderia cenocepacia bacteremia without respiratory colonization in an adult intensive care unit: epidemiological and molecular investigation of an outbreak, Hippokratia, 16(4):317-23, 2012.

[30] V. Gautam, P. Ray, P. Vandamme, S.S. Chatterjee, A. Das, K. Sharma, et al., Identification of lysine positive non fermenting Gram negative bacilli Stenotrophomona smaltophilia and Burkholderia cepacia complex, Indian J Med Microbiol, 27(2):128-33, 2009.